Novel non-steroidal mineralocorticoid receptor antagonists have a better safety profile than steroidal formulations. This Review examines the pro-inflammatory and profibrotic activity of mineralocorticoid receptor activation and discusses the therapeutic potential of MRAs in the treatment of diabetic kidney disease to improve kidney and cardiovascular outcomes.
- Jonatan Barrera-Chimal
- Ixchel Lima-Posada
- Frederic Jaisser